The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment

The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment

Introduction. Simultaneous inhibition of programmed cell death-1 (PD-1)/PD-L1 immune checkpoint and VEGF/VEGFR signaling has a  synergistic antitumor effect in  preclinical models. This article presents the  results of  the  phase III study JAVELIn Renal 101 (NCT02684006), as well as the experience...

Full description

Bibliographic Details
Main Authors: B. Ya. Alekseev, I. M. Shevchuk, V. Р. Aleshin
Format: Article
Language:Russian
Published: Remedium Group LLC 2021-06-01
Series:Медицинский совет
Subjects:
axitinib
avelumab
metastatic renal cell carcinoma
pd-l1
sunitinib
Online Access:https://www.med-sovet.pro/jour/article/view/6209

Similar Items

Similar Items